Julie E Trzil1,2, Isabelle Masseau2, Tracy L Webb3, Chee-Hoon Chang4, John R Dodam2, Hong Liu5, Jessica M Quimby3, Steven W Dow3, Carol R Reinero6,2. 1. IndyVet Emergency and Specialty Hospital, Indianapolis, Indiana, USA. 2. Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA. 3. Center for Immune and Regenerative Medicine, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA. 4. College of Veterinary Medicine, Texas A&M University, College Station, TX, USA. 5. Comparative Internal Medicine Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA. 6. Comparative Internal Medicine Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA reineroc@missouri.edu.
Abstract
OBJECTIVES: The aim of this study was to evaluate the feasibility and efficacy of serially administered adipose-derived mesenchymal stem cells (MSCs) in an experimental feline asthma model. METHODS: Allergic asthma was acutely induced with Bermuda grass allergen in six purpose-bred cats. Five intravenous infusions of allogeneic MSCs (n = 4; MSC-treated) or saline (n = 2; placebo-treated) were administered over the first 130 days after asthma induction. Infusions contained 2 × 106, 4 × 106, 4.7 × 106, 1 × 107 and 1 × 107 cryopreserved MSCs/cat. For thoracic imaging additional cats were enrolled as control groups: four untreated, experimentally asthmatic cats (combined with placebo-treated cats), and six healthy, non-asthmatic cats. Outcome measures included airway eosinophilia, pulmonary mechanics, thoracic computed tomography and several immunologic assays. RESULTS: Cats were assessed for 9 months after treatment. At early points, airway eosinophil percentage was not affected by MSC administration (post-treatment average of days 12, 26, 47, 108 and 133 in MSC-treated cats was 41 ± 15% and in placebo-treated cats it was 34 ± 16%). By month 9, eosinophil percentages in all MSC-treated cats decreased to normal reference intervals (MSC-treated 6%; placebo-treated 20%; normal <17%). Diminished airway hyper-responsiveness was noted in all MSC-treated compared with placebo-treated cats at day 133 (dose of methacholine to double baseline airway resistance: MSC-treated median 22.9 mg/ml [range 6.4-64.0]; individual placebo-treated cats 1.1 and 5.0 mg/ml). Lung attenuation (mean ± SEM MSC-treated -865 ± 12 Hounsfield units [HU]; untreated asthmatics -820 ± 11 HU; P = 0.004) and bronchial wall thickening scores (median [interquartile range] MSC-treated 0 [0-1.5]; untreated asthmatic 11.6 [7.3-27.3]; P = 0.010) were significantly reduced in MSC-treated vs untreated asthmatic cats, consistent with decreased airway remodeling at month 9. No clear immunologic mechanisms by which MSCs act were determined. CONCLUSIONS AND RELEVANCE: MSCs may have a delayed effect in reducing airway inflammation, airway hyper-responsiveness and remodeling in experimentally induced asthmatic cats. Results warrant additional investigation of MSC therapy for asthma in cats.
OBJECTIVES: The aim of this study was to evaluate the feasibility and efficacy of serially administered adipose-derived mesenchymal stem cells (MSCs) in an experimental feline asthma model. METHODS:Allergic asthma was acutely induced with Bermuda grass allergen in six purpose-bred cats. Five intravenous infusions of allogeneic MSCs (n = 4; MSC-treated) or saline (n = 2; placebo-treated) were administered over the first 130 days after asthma induction. Infusions contained 2 × 106, 4 × 106, 4.7 × 106, 1 × 107 and 1 × 107 cryopreserved MSCs/cat. For thoracic imaging additional cats were enrolled as control groups: four untreated, experimentally asthmatic cats (combined with placebo-treated cats), and six healthy, non-asthmatic cats. Outcome measures included airway eosinophilia, pulmonary mechanics, thoracic computed tomography and several immunologic assays. RESULTS:Cats were assessed for 9 months after treatment. At early points, airway eosinophil percentage was not affected by MSC administration (post-treatment average of days 12, 26, 47, 108 and 133 in MSC-treated cats was 41 ± 15% and in placebo-treated cats it was 34 ± 16%). By month 9, eosinophil percentages in all MSC-treated cats decreased to normal reference intervals (MSC-treated 6%; placebo-treated 20%; normal <17%). Diminished airway hyper-responsiveness was noted in all MSC-treated compared with placebo-treated cats at day 133 (dose of methacholine to double baseline airway resistance: MSC-treated median 22.9 mg/ml [range 6.4-64.0]; individual placebo-treated cats 1.1 and 5.0 mg/ml). Lung attenuation (mean ± SEM MSC-treated -865 ± 12 Hounsfield units [HU]; untreated asthmatics -820 ± 11 HU; P = 0.004) and bronchial wall thickening scores (median [interquartile range] MSC-treated 0 [0-1.5]; untreated asthmatic 11.6 [7.3-27.3]; P = 0.010) were significantly reduced in MSC-treated vs untreated asthmatic cats, consistent with decreased airway remodeling at month 9. No clear immunologic mechanisms by which MSCs act were determined. CONCLUSIONS AND RELEVANCE: MSCs may have a delayed effect in reducing airway inflammation, airway hyper-responsiveness and remodeling in experimentally induced asthmatic cats. Results warrant additional investigation of MSC therapy for asthma in cats.
Authors: Katsuyuki Takeda; Tracy L Webb; Fangkun Ning; Yoshiki Shiraishi; Daniel P Regan; Lyndah Chow; Mia J Smith; Shigeru Ashino; Amanda M Guth; Sophie Hopkins; Erwin W Gelfand; Steven Dow Journal: J Immunol Date: 2018-01-19 Impact factor: 5.422
Authors: Kaitlin C Clark; Fernando A Fierro; Emily Mills Ko; Naomi J Walker; Boaz Arzi; Clifford G Tepper; Heather Dahlenburg; Andrew Cicchetto; Amir Kol; Lyndsey Marsh; William J Murphy; Nasim Fazel; Dori L Borjesson Journal: Stem Cell Res Ther Date: 2017-03-20 Impact factor: 6.832
Authors: Carol R Reinero; Isabelle Masseau; Megan Grobman; Aida Vientos-Plotts; Kurt Williams Journal: J Vet Intern Med Date: 2019-04-13 Impact factor: 3.333
Authors: Inês Esteves Dias; Pedro Olivério Pinto; Luís Carlos Barros; Carlos Antunes Viegas; Isabel Ribeiro Dias; Pedro Pires Carvalho Journal: BMC Vet Res Date: 2019-10-22 Impact factor: 2.741
Authors: Amy Wysong; Priscilla Ortiz; Douglas Bittel; Lindsey Ott; Francis Karanu; Michael Filla; Lisa Stehno-Bittel Journal: BMC Vet Res Date: 2021-07-15 Impact factor: 2.741